T-DXd: Updated Results from the DESTINY-Breast Studies and Practical Considerations for Followup
August 3rd 2023Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.
Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB
July 27th 2023Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.
Ongoing Second-Line Trials in Patients with HER2+ mBC and Expert Clinical Perspective
July 27th 2023Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.
Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.
Dr Patel on Safety Data and Biomarker Outcomes With Ide-Cel in High-Risk R/R Multiple Myeloma
July 21st 2023Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.
Use of ADCs in the Second-Line Treatment of HER2+ mBC
July 20th 2023Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.
Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC
July 20th 2023Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.
Dr Damodaran on the ELAINE-3 Trial in Patients With ESR1-Mutated ER+/HER2– Metastatic Breast Cancer
July 19th 2023Senthil Damodaran, MD, PhD, discusses the rationale for the phase 3 ELAINE-3 trial in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.